Ion Channel Solutions

High-Quality PrecisION^™ Products for Target Discovery, Hit Screening, Lead Optimization, and Safety Studies

Ion channels continue to be an important therapeutic target for a wide range of indications, including arrhythmia, hypertension, local anesthesia, pain, stroke, epilepsy, depression, bipolar disorder, cystic fibrosis, cardiac arrhythmias, COPD, autoimmune disorders, and diabetes. They are an appealing target to develop therapeutics against rare channelopathies, since many of these diseases are caused by the mutation of a single gene. Ion channels not only constitute a significant class of drug targets, they are also critical for evaluating drug safety, including being part of the U.S. FDA required safety testing for any drug targeted against human disease.

Eurofins DiscoverX^®’s comprehensive portfolio of functionally validated ion channel products is comprised of optimized PrecisION stable cell lines and ready-to-assay cells for cell-based electrophysiological experiments, PathHunter® pharmacotrafficking assays for pharmacochaperone discovery, and an hERG ion channel membrane preps for safety binding studies.

The vast ion channel product solutions include assessment of voltage-gated, ligand-gated, and several other targets for screening ion channel inhibitors for your drug discovery and safety applications. The ion channel cell lines are pharmacologically and functionally validated using in-house discovery and safety services laboratories. Their biophysical and pharmacological properties are characterized electrophysiologically using conventional manual patch-clamp and multiple automated patch-clamp platforms by experienced electrophysiologists in both Eurofins Discovery services and Eurofins DiscoverX products laboratories.